Pfizer Inc.'s Drug to Treat Tuberculosis in Short Supply

The Food and Drug Administration has added Pfizer Inc's tuberculosis treatment rifampin to its list of drugs in short supply, the latest in a growing number of spottily available TB medications. The FDA noted in a post on its website on Monday that the injectible antibiotic will be in short supply until the end of June. The cause of the shortage is a manufacturing delay, it said. Rifampin is one of the most potent and widely used TB drugs, and its shortage comes amid an increased prevalence of the disease around the world, though TB rates in the United States fell to an all-time low last year.